Drug · CHEMBL481
IRINOTECAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. IRINOTECAN. Drugs and targets, record CHEMBL481. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL481
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TOP1 | DNA topoisomerase 1 | DNA topoisomerase I inhibitor | INHIBITOR | https://conductscience.org/library/genes/7150 |
Source ChEMBL
Diseases146
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| colorectal cancer | Approval | TTD | 475 | 474 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| malignant pancreatic neoplasm | Phase 3 | ClinicalTrials.gov | 103 | 103 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| pancreatic neoplasm | Phase 3 | ClinicalTrials.gov | 101 | 101 | https://conductscience.org/library/drugs?q=MONDO_0021040 |
| pancreatic adenocarcinoma | Phase 3 | ClinicalTrials.gov | 84 | 84 | https://conductscience.org/library/drugs?q=MONDO_0006047 |
| gastric cancer | Phase 3 | ClinicalTrials.gov | 74 | 74 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| rectal cancer | Phase 3 | ClinicalTrials.gov | 68 | 68 | https://conductscience.org/library/drugs?q=MONDO_0006519 |
| small cell lung carcinoma | Phase 3 | ClinicalTrials.gov | 65 | 65 | https://conductscience.org/library/drugs?q=MONDO_0008433 |
| pancreatic ductal adenocarcinoma | Phase 3 | ClinicalTrials.gov | 51 | 51 | https://conductscience.org/library/drugs?q=MONDO_0005184 |
| gastric adenocarcinoma | Phase 3 | ClinicalTrials.gov | 44 | 44 | https://conductscience.org/library/drugs?q=MONDO_0005036 |
| exocrine pancreatic carcinoma | Phase 3 | ClinicalTrials.gov | 43 | 43 | https://conductscience.org/library/drugs?q=MONDO_0005192 |
1 to 10 of 146Source Open Targets
See all 146 diseasesTrials1,362
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 24 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 171 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00265850 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Phase 3 | 2,334 | 2017-04-26 | irinotecan | Its name | ClinicalTrials.gov |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Phase 3 | 1,253 | 2022-04-26 | irinotecan | Its name | ClinicalTrials.gov |
| NCT00154102 | Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) | Phase 3 | 1,221 | 2011-02-23 | irinotecan | Its name | ClinicalTrials.gov |
| NCT00339183 | Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone | Phase 3 | 1,186 | 2014-05-06 | folfiri | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01183780 | A Study in Second Line Metastatic Colorectal Cancer | Phase 3 | 1,072 | 2015-07-15 | irinotecan | Its name | ClinicalTrials.gov |
| NCT00115765 | PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study | Phase 3 | 1,053 | 2010-09-14 | irinotecan | Its name | ClinicalTrials.gov |
| NCT01571284 | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | Phase 3 | 781 | 2018-02-27 | irinotecan | Its name | ClinicalTrials.gov |
| NCT04083235 | A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment | Phase 3 | 770 | 2024-03-13 | irinotecan | Its name | ClinicalTrials.gov |
| NCT00457691 | Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer | Phase 3 | 768 | 2011-06-03 | irinotecan | Its name | ClinicalTrials.gov |
| NCT02564263 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | Phase 3 | 628 | 2019-11-20 | irinotecan | Its name | ClinicalTrials.gov |
1 to 10 of 1,362
See all 1,362 trialsComparisons in its trials182
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: deaths from any cause | 507 of 624 | 499 of 629 | 1,253 | NCT02753127 | Trial comparisons |
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: serious adverse events | 234 of 622 | 201 of 610 | 1,232 | NCT02753127 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Safety - Number of Patients Experiencing Any Adverse Event | 599 of 600 | 597 of 602 | 1,202 | NCT00154102 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: serious adverse events | 263 of 600 | 204 of 602 | 1,202 | NCT00154102 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Participants With No Residual Tumor After Metastatic Surgery | 29 of 599 | 10 of 599 | 1,198 | NCT00154102 | Trial comparisons |
| Arm A: FOLFOX or FOLFIRI + Bevacizumab vs Arm B: FOLFOX or FOLFIRI + Cetuximab: serious adverse events | 98 of 559 | 111 of 578 | 1,137 | NCT00265850 | Trial comparisons |
| FOLFIRI + Ramucirumab vs FOLFIRI + Placebo: serious adverse events | 198 of 529 | 175 of 528 | 1,057 | NCT01183780 | Trial comparisons |
| Panit. Plus Bevacizumab With Chemotherapy vs Bevacizumab With Chemotherapy: serious adverse events | 306 of 518 | 188 of 510 | 1,028 | NCT00115765 | Trial comparisons |
| FOLFIRI + Sunitinib vs FOLFIRI + Placebo: Number of Participants With Overall Confirmed Objective Response | 124 of 386 | 128 of 382 | 768 | NCT00457691 | Trial comparisons |
| FOLFIRI + Sunitinib vs FOLFIRI + Placebo: serious adverse events | 170 of 384 | 111 of 379 | 763 | NCT00457691 | Trial comparisons |
1 to 10 of 182
See all 182 comparisons in its trialsPapers from its trials636
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| 2-Back Task | 1 | 1 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL481
GET https://conductscience.org/api/drugs/v1/CHEMBL481/diseases?page=2